Skip to Content
Merck

Skip To

C4801

Sigma-Aldrich

Cyclo(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl])

≥95% (HPLC), powder

Synonym(s):

Cyclosomatostatin

Sign Into View Organizational & Contract Pricing

Select a Size

Change View
10 μG
CA$637.00

About This Item

Empirical Formula (Hill Notation):
C44H57N7O6
CAS Number:
Molecular Weight:
779.97
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.32

CA$637.00


Please contact Customer Service for Availability

Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥95% (HPLC)

form

powder

color

white

solubility

H2O: 1 mg/mL, clear, colorless

storage temp.

−20°C

SMILES string

O=C(N[C@H](C(N[C@@]1([H])[C@@H](C)OCC2=CC=CC=C2)=O)CCCCN)[C@H](NC([C@@H](NC(CCCCCCNC1=O)=O)CC3=CC=CC=C3)=O)CC4=CNC5=C4C=CC=C5

InChI

1S/C44H57N7O6/c1-30(57-29-32-18-8-5-9-19-32)40-44(56)46-25-15-3-2-10-23-39(52)48-37(26-31-16-6-4-7-17-31)42(54)50-38(27-33-28-47-35-21-12-11-20-34(33)35)43(55)49-36(41(53)51-40)22-13-14-24-45/h4-9,11-12,16-21,28,30,36-38,40,47H,2-3,10,13-15,22-27,29,45H2,1H3,(H,46,56)(H,48,52)(H,49,55)(H,50,54)(H,51,53)/t30-,36+,37+,38-,40+/m1/s1

InChI key

YHVHQZYJGWGAKN-ZUWUZHNASA-N

Gene Information

human ... SST(6750)
mouse ... SST(20604)
rat ... SST(24797)

Amino Acid Sequence

cyclo-Phe-Trp-Lys-Thr-Bzl

Application

Cyclo(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl]) has been used as a somatostatin antagonist to study its effects on sleep in rats to infer the role of endogenous somatostatin in the physiologic modulation of REM sleep (REMS) [1], as an somatostatin (SST) antagonist to study its effects on elemental-induced intestinal atrophy in rats [2], as an SST receptor antagonist to eliminate the effect of somatostatin on catecholamine [3].

Biochem/physiol Actions

Cyclo(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl]) (cSSTA) is a cyclic somatostatin (SST) analog and is a somatostatin receptor antagonist. It is involved in blocking the effect of somatostatin, such as airway β-adrenergic function and regulation of acetylcholine release. cSSTA is also involved in blocking the effect of somatostatin of hormone release and corticotropin-releasing factor-induced suppression of gastric emptying.[4]
Cyclo(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[Bzl]), also known as cyclosomatostatin. Inhibition of somatostatin receptors by cyclosomatostatin induces catalepsy in rats.[5]

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
D9378C2901Q4990
QBP1 ≥95% (HPLC)

Q4990

QBP1

assay

≥95% (HPLC)

assay

≥95%

assay

≥95% (HPLC)

assay

≥95% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

200

Quality Level

100

Quality Level

200

Quality Level

100

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

solubility

H2O: 1 mg/mL, clear, colorless

solubility

1 M HCl: soluble, ethanol: insoluble

solubility

-

solubility

H2O: >1 mg/mL

color

white

color

-

color

-

color

white


Still not finding the right product?


Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Ya-Ling Zhai et al.
PloS one, 9(7), e101779-e101779 (2014-07-10)
Endothelial injury, which may present clinically as hypertension, proteinuria and increased von Willebrand Factor (vWF) level, is a common manifestation in IgA nephropathy (IgAN). However, causal factors for endothelial injury in IgAN are not completely understood. An imbalance of vascular
Sylvie Remy et al.
PloS one, 9(3), e92677-e92677 (2014-03-26)
There is increasing epidemiologic evidence that arsenic exposure in utero is associated with adverse pregnancy outcomes and may contribute to long-term health effects. These effects may occur at low environmental exposures but the underlying molecular mechanism is not clear. We
Monica Autiero et al.
Nature medicine, 9(7), 936-943 (2003-06-11)
Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase (RTK) Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1